NGT BioPharma Consultants understand the challenges companies face when selecting a candidate molecule(s) to advance into preclinical development. To increase the efficiency and effectiveness of this process, we work collaboratively with our clients to provide a clear assessment of a potential asset’s attributes, including risks, to ensure critical experiments are prioritized. 

We generate fit-for-purpose late discovery and investigative research plans for our clients by leveraging our team’s collective knowledge and experience in small and large molecules (Mabs, duobodies, proteins, cell therapy, gene therapy, and other new modalities). Our advice, and recommendations, also leverages our broader team’s drug development expertise in the Nonclinical Sciences, CMC, Regulatory and Quality/Compliance disciplines.